Rheumatoid arthritis
Conditions
Interventions
Experimental group:Acupuncture + basic medication
Sponsors
The First Affiliated Hospital of China Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) Age 18-65 years old male or female; (2) Meet the 2010 classification standards of the American College of Rheumatology or the European League of Rheumatology; (3) The condition meets the following conditions: A. Rheumatoid arthritis is in A state of disease activity: a) Have at least three painful and swollen joints; b)DAS28 > 2.6 and CDAI > 2.8 (the disease activity score in 28 joints [the disease activity score in 28 joints ESR-based or CRP-basedDAS(ESR)or DAS28(CRP)] score) C) Meet at least one of the following conditions: I. Erythrocyte sedimentation rate (ESR) =45mm/h; (upper limit of normal value) ? C-reactive protein (CRP) =15mg/dl; (upper limit of normal value) ?. Morning stiffness > 1 hour B. CR function is classified as grade I-III; (4) At least one anti-rheumatic drug (traditional anti-rheumatic drugs (DMARDs) non-steroidal anti-inflammatory drugs oral glucocorticoids etc.) is currently being used or considered appropriate by a doctor and the dose is stable for > 4 weeks; (5) have not used any Chinese medicine treatment (traditional Chinese medicine acupuncture massage etc.) within one month; (6) agree not to participate in other studies and not to receive other treatments for rheumatoid arthritis and immunomodulators during the period of participation in this study; (7) Understand and sign informed consent prior to any steps related to this study and comply with the requirements of this study;
Exclusion criteria
Exclusion criteria: Patients who meet any of the following criteria will be excluded from the study: (1) Overlapping other rheumatic diseases, such as systemic lupus erythematosus, Sjogren's syndrome, severe knee osteoarthritis, etc.; (2) Patients with serious diseases, including (but not limited to) the following: patients with fasting > 8mmol/L after drug intervention and > 13mmol/L 2 hours after meal, grade 2 or above diabetes and hypertension, complicated with serious diseases such as heart, brain, blood, liver, kidney, respiratory (including pulmonary interstitial diseases and severely infected people); (3) Taking anti-rheumatic drugs, immunosuppressants, hormones, etc., other than the drugs specified in the trial, within one month before the start of the trial; (4) there is incomplete skin at the selected acupoints and allergy to the selected drugs or acupuncture in the treatment plan; (5) Women preparing for pregnancy, pregnancy, lactating period, men who cannot use contraception; (6) Participated in other clinical investigators in the study or in the previous 3 months; Other patients whom the clinician deems inappropriate to study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients with a DAS28 score achieving remission; | — |
Secondary
| Measure | Time frame |
|---|---|
| Joint swelling ;Inflammatory factor levels;The visual analogue Scale of pain (VAS);Proportion of patients who achieved a clinical disease activity index (CDAI) response;Acupuncture sensation evaluation;Morning stiffness score;Muscle mass and function;Patient health rating scale scores;Joint function grade; | — |
Countries
China
Contacts
Public ContactZhang Jie
The First Affiliated Hospital of China Medical University
Outcome results
None listed